Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)

Transfus Med. 2019 Jun;29(3):146-148. doi: 10.1111/tme.12615.

Abstract

Clinical question: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage?

Evidence from trial: In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP.

Keywords: RCT; caplacizumab; plasma exchange; thrombotic thrombocytopenic pupura.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Female
  • Humans
  • Male
  • Platelet Count
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Purpura, Thrombotic Thrombocytopenic / pathology
  • Recurrence
  • Single-Domain Antibodies / administration & dosage*
  • Single-Domain Antibodies / adverse effects

Substances

  • Single-Domain Antibodies
  • caplacizumab

Supplementary concepts

  • Thrombotic thrombocytopenic purpura, acquired